Treatment of Multiple Myeloma: Best Practices from City of Hope and Satellites

home / satellite-sessions / treatment-of-multiple-myeloma-best-practices-from-city-of-hope-and-satellites

Experts from City of Hope reflect on the current treatment landscape of multiple myeloma and how clinical data are applied to their practice within the main campus and satellite institutions.

Clinical Scenario: A 61-Year-Old Woman with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM)

EP. 1: Clinical Scenario: A 61-Year-Old Woman with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM)

Michael Rosenzweig, MD, MS;Ashwin Kashyap, MD;Neel Talwar, MD;Natasha Garg, DO, MS
August 29th 2023

Michael Rosenzweig, MD, MS, presents the clinical scenario of a 61-year-old woman with transplant-eligible newly diagnosed multiple myeloma to the panel for discussion.

Induction Treatment Regimens for Patients With Transplant-Eligible NDMM

EP. 2: Induction Treatment Regimens for Patients With Transplant-Eligible NDMM

Michael Rosenzweig, MD, MS;Ashwin Kashyap, MD;Neel Talwar, MD;Natasha Garg, DO, MS
August 29th 2023

A panel of experts from City of Hope and satellite clinics review the available frontline therapy options for patients with transplant-eligible newly diagnosed multiple myeloma.

Treatment Strategies for Patients With High-Risk NDMM

EP. 3: Treatment Strategies for Patients With High-Risk NDMM

Michael Rosenzweig, MD, MS;Ashwin Kashyap, MD;Neel Talwar, MD;Natasha Garg, DO, MS
September 6th 2023

Natasha Garg, DO, MS, and Neel Talwar, MD, explain the resources they utilize at City of Hope for treating patients with high-risk newly diagnosed multiple myeloma.

Clinical Scenario: A 68-Year-Old Man With Transplant-Ineligible NDMM

EP. 4: Clinical Scenario: A 68-Year-Old Man With Transplant-Ineligible NDMM

Michael Rosenzweig, MD, MS;Ashwin Kashyap, MD;Neel Talwar, MD;Natasha Garg, DO, MS
September 6th 2023

Michael Rosenzweig, MD, MS, presents the clinical scenario of a 68-year-old man with transplant-ineligible newly diagnosed multiple myeloma to the expert panel for discussion.

Selecting Between DRd and VRd Combination Regimens for Patients With Transplant-Ineligible NDMM

EP. 5: Selecting Between DRd and VRd Combination Regimens for Patients With Transplant-Ineligible NDMM

Michael Rosenzweig, MD, MS;Ashwin Kashyap, MD;Neel Talwar, MD;Natasha Garg, DO, MS
September 13th 2023

A panel of experts explain how they select between the DRd (daratumumab, lenalidomide, dexamethasone) and VRd (bortezomib, lenalidomide, dexamethasone) treatment regimens for patients with transplant-ineligible newly diagnosed multiple myeloma.

Factors for Consideration When Treating Frail Patients With Transplant-Ineligible NDMM

EP. 6: Factors for Consideration When Treating Frail Patients With Transplant-Ineligible NDMM

Michael Rosenzweig, MD, MS;Ashwin Kashyap, MD;Neel Talwar, MD;Natasha Garg, DO, MS
September 13th 2023

Focused discussion on tailoring treatment decision-making for patients with multiple myeloma classified as frail.

Bone Disease Prophylaxis in Patients With Transplant-Eligible NDMM

EP. 7: Bone Disease Prophylaxis in Patients With Transplant-Eligible NDMM

Michael Rosenzweig, MD, MS;Ashwin Kashyap, MD;Neel Talwar, MD;Natasha Garg, DO, MS
September 20th 2023

Expert panelists discuss the options for preventing bone disease in patients with multiple myeloma, including osteonecrosis of the jaw.

Clinical Scenario: A 61-Year-Old Woman With Relapsed/Refractory Multiple Myeloma (R/R MM)

EP. 8: Clinical Scenario: A 61-Year-Old Woman With Relapsed/Refractory Multiple Myeloma (R/R MM)

Michael Rosenzweig, MD, MS;Ashwin Kashyap, MD;Neel Talwar, MD;Natasha Garg, DO, MS
September 20th 2023

Michael Rosenzweig, MD, MS, presents the clinical scenario of a 61-year-old woman with relapsed/refractory multiple myeloma for panel discussion.

Choosing Between Bispecific or CAR T-Cell Therapy for Patients With Multiple Myeloma

EP. 9: Choosing Between Bispecific or CAR T-Cell Therapy for Patients With Multiple Myeloma

Michael Rosenzweig, MD, MS;Ashwin Kashyap, MD;Neel Talwar, MD;Natasha Garg, DO, MS
September 27th 2023

Shared insight on the factors to consider when choosing between a bispecific therapy and CAR T-cell therapy for a patient with multiple myeloma.

Toxicity Management in Patients With Multiple Myeloma

EP. 10: Toxicity Management in Patients With Multiple Myeloma

Michael Rosenzweig, MD, MS;Ashwin Kashyap, MD;Neel Talwar, MD;Natasha Garg, DO, MS
September 27th 2023

Experts explain strategies for toxicity management in patients receiving treatment for multiple myeloma, including monitoring risk of CRS.

Expert Perspectives on Quadruplet Therapy Regimens for Patients With Multiple Myeloma

EP. 11: Expert Perspectives on Quadruplet Therapy Regimens for Patients With Multiple Myeloma

Michael Rosenzweig, MD, MS;Ashwin Kashyap, MD;Neel Talwar, MD;Natasha Garg, DO, MS
October 4th 2023

The panel shares some personal experiences with treating patients with multiple myeloma with a quadruplet therapy regimen.

Looking Ahead in the Multiple Myeloma Treatment Landscape

EP. 12: Looking Ahead in the Multiple Myeloma Treatment Landscape

Michael Rosenzweig, MD, MS;Ashwin Kashyap, MD;Neel Talwar, MD;Natasha Garg, DO, MS
October 4th 2023

Experts from City of Hope close out their panel on multiple myeloma management by identifying unmet needs and sharing what excites them in the future evolution of the treatment landscape.

Experts in the field of multiple myeloma gathered to discusses treatment options including bispecific antibodies CAR T-cell therapy, and the importance of collaborative decision-making across clinics.

EP. 13: CAR T-Cell Therapy Vs Bispecific Antibodies As Multiple Myeloma Treatment

Rina Lokaj
November 23rd 2023

Experts in the field of multiple myeloma gathered to discusses treatment options including bispecific antibodies CAR T-cell therapy, and the importance of collaborative decision-making across clinics.